Indeed, TRAIL-mediated cytotoxic activity upon antiCLL-1:TRAIL treatment was strongly enhanced and also served to effectively potentiate ADCC induced by therapeutic antibodies on both solid and hematological cancers [39]. The gene discussed is TNFSF10; the disease is hematopoietic and lymphoid cell neoplasm.